<div id="readability-page-1"><div><p>Global markets are being pulled in different directions by sticky inflation, uneven growth, and shifting trade patterns, and that mix is creating room for carefully chosen penny stocks with stronger balance sheets. While many low-priced stocks burn through cash and stall out, the Elite Penny Stocks screener focuses on companies that appear better equipped to fund their plans. Against a backdrop of persistent price pressures, changing consumer signals, and active central banks, this article highlights 3 stocks from the screener that stand out as potential high-upside ideas for investors willing to do the work on smaller companies.</p> <h2>Cronos Group (TSX:CRON)</h2> <p><strong>Overview:</strong> Cronos Group is a cannabinoid company that cultivates, produces, and sells cannabis products, including dried flower, pre-rolls, vapes, edibles, oils, and tinctures, under brands such as Spinach, Lord Jones, Lit, and Peace Naturals across Canada, Israel, and select international markets.</p> <p><strong>Operations:</strong> The company generates CA$146.6 million from cultivation, manufacturing, and marketing of cannabis and cannabis-derived products, with revenue primarily from Canada (CA$90.3 million), followed by Israel (CA$41.8 million) and other countries (CA$14.5 million).</p> <p><strong>Market Cap:</strong> CA$1.35b</p> <p>Cronos Group may catch your eye if you want cannabis exposure with both upside potential and clear risks to weigh. The company has CA$146.6 million in product revenue, strong brand traction in higher margin categories such as vapes and edibles, and a sizeable cash position with no debt, which supports product launches such as new Spinach vapes and pre-rolls. At the same time, Cronos still reports losses and faces regulatory uncertainty in key markets such as Israel and Germany, and analysts see a wide range of possible outcomes in their price targets. For investors who are willing to do deeper work, the tension between its cash-rich balance sheet, growth ambitions, and ongoing profitability challenges is a key focus.</p> <p>Cash rich, loss making, and operating in tightly regulated markets, Cronos looks like a puzzle that many investors may only be half reading. Get the full picture with the Cronos Group financial health report</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/49c2cca9-f26c-48fc-add2-8e319554b2fa/chart/revenue-and-expenses-breakdown/query-ZGF0ZT0yMDI2LTA1LTEw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/49c2cca9-f26c-48fc-add2-8e319554b2fa/chart/revenue-and-expenses-breakdown/query-ZGF0ZT0yMDI2LTA1LTEw"/><figcaption>TSX:CRON Revenue &amp; Expenses Breakdown as at May 2026</figcaption></figure> <h2>CEMATRIX (TSX:CEMX)</h2> <p><strong>Overview:</strong> CEMATRIX manufactures and installs cellular concrete across North America, supplying lightweight, pumpable concrete for infrastructure, industrial, and commercial projects such as roads, bridges, tunnels, and slope stabilization. Its products are used where contractors want to reduce weight, improve insulation, or fill difficult spaces that conventional concrete struggles to reach.</p> <p><strong>Market Cap:</strong> CA$80.89 million</p> <p>CEMATRIX operates at the intersection of two notable themes for construction investors: infrastructure spending and demand for lower carbon materials. Revenue of CA$45.09 million and net income of CA$4.06 million in 2025, together with analysts expecting earnings growth above 20% a year, indicate that some investors view the business as scaling rather than just surviving. The record CA$76.4 million backlog and fresh contract wins in 2026 highlight work in hand, yet results remain lumpy, Q1 2026 showed a net loss of CA$1.16 million, and the business is concentrated in North America with high external borrowing. In addition, a sizeable buyback program introduces another factor that many investors may not have fully weighed yet.</p> <p>Accelerating orders and a CA$76.4 million backlog suggest CEMATRIX might be more than a niche contractor, yet the Q1 2026 loss and high borrowing raise big questions that the analysis report for CEMATRIX only starts to answer.</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/bd3a326e-3c48-4cd3-ae22-6e576f517240/chart/revenue-and-expenses-breakdown/query-ZGF0ZT0yMDI2LTA1LTEw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/bd3a326e-3c48-4cd3-ae22-6e576f517240/chart/revenue-and-expenses-breakdown/query-ZGF0ZT0yMDI2LTA1LTEw"/><figcaption>TSX:CEMX Revenue &amp; Expenses Breakdown as at May 2026</figcaption></figure> <h2>Cannara Biotech (TSX:LOVE)</h2> <p><strong>Overview:</strong> Cannara Biotech is a vertically integrated Canadian cannabis company that grows, processes, and sells branded cannabis and CBD products under TRIBAL, nugz, and ORCHID CBD, while also generating income from real estate operations.</p> <p><strong>Operations:</strong> Cannara Biotech generates about CA$108.8 million from cannabis operations and CA$3.9 million from real estate, with all reported revenue of roughly CA$113.0 million coming from Canada.</p> <p><strong>Market Cap:</strong> CA$174.8 million</p> <p>Cannara Biotech sits at the intersection of premium cannabis branding and scaled indoor production, with vertically integrated facilities, consistent positive adjusted EBITDA over 20 quarters, and a growing national retail presence, including strong share in Quebec. At the same time, recent quarters show margin pressure, reliance on a single country, higher external borrowing and insider selling. Analysts are currently modeling sizeable earnings growth and a higher price target than today. For investors who want a cannabis stock where operating execution, export ambitions, and valuation expectations all matter, this is a company that may warrant closer reading of the numbers, the growth narrative, and the risks in the plan.</p> <p>Accelerating branding, 20 quarters of positive adjusted EBITDA and export ambitions could mean Cannara Biotech’s story is only half told, and the analyst forecasts for Cannara Biotech might reveal the twist investors are missing</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d6b315ed-ef67-43ed-b623-7019e7826bc8/chart/earnings-and-revenue-history/query-ZGF0ZT0yMDI2LTA1LTEw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d6b315ed-ef67-43ed-b623-7019e7826bc8/chart/earnings-and-revenue-history/query-ZGF0ZT0yMDI2LTA1LTEw"/><figcaption>TSX:LOVE Earnings &amp; Revenue History as at May 2026</figcaption></figure> <p>The three stocks in this article are just a starting point, and the full Elite Penny Stocks screener surfaces 11 more companies where cash reserves, funding runways, and business models line up into equally compelling stories. Use Simply Wall St to identify, analyze, and filter for the exact catalysts and narratives that matter to you so you can focus on penny stock ideas backed by stronger balance sheets.</p> <h2>Take Control of Your Investment Journey</h2> <p> If CEMATRIX or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen.             Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates.             Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives.             By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.         </p> <h2>Seeking Fresh Alternatives Before They Fly?</h2> <p>Some of the most interesting ideas often sit under the radar for now, right before a breakout or sharp momentum shift. Scan these fresh sets of stocks before the crowd and consider your options early.</p> <ul> <li>Spot companies with strong cash flows and solid balance sheets by running the 7 high quality undervalued stocks, while it matters and before attention chases the next story.</li> <li>Track resilient businesses that may hold up when others stumble by scanning the 11 resilient stocks with low risk scores and see which stocks still look robust if sentiment drops.</li> <li>Review early leaders in next generation automation by using the curated 32 robotics and automation stocks and filter for stocks that might align with long-term momentum from real-world adoption.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data         and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your         financial situation. We aim to bring you long-term focused analysis driven by fundamental data.         Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.         Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><div><p>• Dividend Powerhouses (3%+ Yield)<br/>• Undervalued Small Caps with Insider Buying<br/>• High growth Tech and AI Companies</p><p>Or build your own from over 50 metrics.</p></div><p>Explore Now for Free</p></div></div></div>

CRON

CBIH

<p>The article highlights three elite penny stocks with strong balance sheets: Cronos Group (TSX:CRON), CEMATRIX (TSX:CEMX), and Cannara Biotech (TSX:LOVE). Cronos Group, a cannabis company, has a market cap of CA$1.35 billion and generates CA$146.6 million in revenue but faces profitability challenges. CEMATRIX, with a market cap of CA$80.89 million, specializes in cellular concrete and has a CA$76.4 million backlog, though it reported a net loss in Q1 2026. Cannara Biotech, valued at CA$174.8 million, generates CA$113 million in revenue but faces margin pressures and high borrowing. Investors are encouraged to analyze these companies further for potential upside.</p>

3 Elite Penny Stocks With Cash Rich Balance Sheets And Upside